Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03755791 |
Recruitment Status :
Active, not recruiting
First Posted : November 28, 2018
Last Update Posted : March 22, 2024
|
Sponsor:
Exelixis
Information provided by (Responsible Party):
Exelixis
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Actual Primary Completion Date : | March 8, 2021 |
Estimated Study Completion Date : | December 1, 2024 |
Certification/Extension First Submitted : | March 8, 2022 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):